Defining Inhibitory Mechanisms of Novel CCRS-targeted Microbicide Candidates
定义新型 CCRS 靶向杀菌剂候选物的抑制机制
基本信息
- 批准号:7418076
- 负责人:
- 金额:$ 53.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-06-06 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAnimal ModelAntiviral AgentsAreaBindingCCL3L1 geneCCR5 geneCell Differentiation processCell surfaceCellsCellular biologyChemokine (C-C Motif) Receptor 5ClassCollaborationsDataDoseEndocytosisGTP-Binding ProteinsGenetic PolymorphismGenotypeGoalsHIV-1HumanInfectionKineticsKnowledgeLateralLigandsLinkMediatingMembraneModelingMolecular ProbesMutateNormal CellNumbersPersonal SatisfactionPopulationPredispositionPrimatesProcessProductionPromoter RegionsProtein BiosynthesisRANTESRangeRateRecombinantsRecyclingResearch DesignRouteSafetySeriesSignal PathwaySignal TransductionSiteStructural GenesT-LymphocyteTestingTissuesVariantVirusanalogbasechemokinecostdensitydesigndimerimprovedinhibitor/antagonistmacrophagemicrobicidemigrationmonocytemutantnovelpreventprogramsprotein degradationreceptorreceptor internalizationresearch studysimian human immunodeficiency virustraffickingvaginal transmission
项目摘要
Project 1 - The goal of Project 1 is to define the mechanism of action of three new chemokine analogues
with potent activity in blocking HIV-1 entry via CCR5. These fully recombinant molecules display three
distinct activity profiles: (group I) CCR5 blockade without signaling activity or receptor internalization; (group
II), CCR5 rapid internalization with signaling activity; and (group III), moderate CCR5 internalization and
blockade without signaling activity. These new molecules have significant potential advantages in terms of
safety and cost of production ..over currenynh[b^ fwither, irrtpr.pvejTients.,p,n
these bahdidate'microbicides requires more detailed knowledge of their mechanisms of action. We will
define the route to intracellular sequestration for group II molecules, and compare with that of the group III
molecules. We will examine a number of hypotheses to explain prolonged antiviral activity in the absence of
intracellular receptor sequestration (group I) or with moderate internalization (group III), including changes in
CCR5 dimer formation, altered receptor localization in the membrane, allosteric effects, and receptor
internalization independent of G-protein-linked signaling. We will also examine the impact of CCR5, CCL5,
and CCL3L1 genetic polymorphisms on CCR5 protein synthesis and turnover rate. These studies are
designed to investigate variability in the susceptibility of primary target cells from normal human donors to
each of the new inhibitors. We will also use a panel of mutant CCR5 molecules to examine structural
correlates of activity. We will use this information on mechanism and target cell variability to develop new
molecules with even better activity profiles, and we will perform coordinated experiments with other projects
in this Program to relate our findings in cell-based models to the effects of current and new CCR5 inhibitors
in tissue explant and whole animal models. This approach will generate better and safer CCR5 inhibitors that
can be produced on a scale suitable for stopping the spread of HIV/AIDS in the most-impacted areas.
项目1 -项目1的目标是确定三种新的趋化因子类似物的作用机制
具有阻断HIV-1通过CCR 5进入的有效活性。这些完全重组的分子展示了三个
不同的活性谱:(组I)CCR 5阻断而无信号传导活性或受体内化;(组II)CCR 5阻断而无信号传导活性或受体内化。
II),具有信号传导活性的CCR 5快速内化;和(组III),中度CCR 5内化和
没有信号传导活性的阻断。这些新分子在以下方面具有显著的潜在优势:
安全和生产成本。超过当前[B],p,n
这些杀微生物剂需要更详细地了解它们的作用机制。我们将
定义II类分子的胞内螯合途径,并与III类分子进行比较
分子。我们将研究一些假设,以解释在缺乏抗病毒药物的情况下延长抗病毒活性。
细胞内受体螯合(I组)或中度内化(III组),包括
CCR 5二聚体形成、膜中受体定位改变、变构效应和受体
不依赖于G蛋白连接的信号转导的内化。我们还将研究CCR 5,CCL 5,
CCL 3L 1基因多态性对CCR 5蛋白合成和周转率的影响。这些研究
旨在研究来自正常人供体的原代靶细胞对
每一种新的抑制剂我们还将使用一组突变的CCR 5分子来检查结构
活动的相关性。我们将利用这些关于机制和靶细胞变异性的信息来开发新的
分子具有更好的活性特征,我们将与其他项目进行协调实验,
在这个项目中,我们将在基于细胞的模型中的发现与当前和新的CCR 5抑制剂的作用联系起来
在组织外植体和整个动物模型中。这种方法将产生更好、更安全的CCR 5抑制剂,
能够以适合于在受影响最严重的地区阻止艾滋病毒/艾滋病蔓延的规模生产。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DONALD E MOSIER其他文献
DONALD E MOSIER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DONALD E MOSIER', 18)}}的其他基金
Modeling HIV-1 primary transmission in vitro and in vivo
HIV-1 初次传播的体外和体内建模
- 批准号:
8434156 - 财政年份:2011
- 资助金额:
$ 53.24万 - 项目类别:
Modeling HIV-1 primary transmission in vitro and in vivo
HIV-1 初次传播的体外和体内建模
- 批准号:
8238279 - 财政年份:2011
- 资助金额:
$ 53.24万 - 项目类别:
Modeling HIV-1 primary transmission in vitro and in vivo
HIV-1 初次传播的体外和体内建模
- 批准号:
8627538 - 财政年份:2011
- 资助金额:
$ 53.24万 - 项目类别:
Modeling HIV-1 primary transmission in vitro and in vivo
HIV-1 初次传播的体外和体内建模
- 批准号:
8113111 - 财政年份:2011
- 资助金额:
$ 53.24万 - 项目类别:
Cross-reactive HERV immunity to combat HIV-1 infection
交叉反应性 HERV 免疫对抗 HIV-1 感染
- 批准号:
7914339 - 财政年份:2009
- 资助金额:
$ 53.24万 - 项目类别:
Cross-reactive HERV immunity to combat HIV-1 infection
交叉反应性 HERV 免疫对抗 HIV-1 感染
- 批准号:
7737332 - 财政年份:2009
- 资助金额:
$ 53.24万 - 项目类别:
Improved Humanized Mouse Models for Vaccine Development
用于疫苗开发的改进人源化小鼠模型
- 批准号:
7689165 - 财政年份:2008
- 资助金额:
$ 53.24万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 53.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




